evotaz- atazanavir and cobicistat tablet
a-s medication solutions - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg) - atazanavir 300 mg - evotaz® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults. limitations of use: evotaz is contraindicated: table 1 displays drugs that are contraindicated with evotaz. alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antianginal ranolazine potential for serious and/or life-threatening reactions. antiarrhythmics dronedarone potential for increased dronedarone concentrations. anticonvulsants carbamazepine, phenobarbital, phenytoin potential for decreased atazanavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance. antigout colchicine contraindicated in patients with renal and/or hepatic impairment due to the potential for serious and/or life-threatening reactions. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeut
genvoya- elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide tablet
gilead sciences, inc. - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir alafenamide fumarate (unii: fwf6q91tzo) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - genvoya is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of genvoya [see clinical studies (14)]. coadministration of genvoya is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of genvoya and possible resistance) are listed below [see drug interactions (7.5) and clinical pharmacology (12.3)] . - alpha 1-adrenoreceptor antagonist: alfuzosin - anticonvulsants: carbamazepine, phen
stribild- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated
state of florida doh central pharmacy - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - stribild® is indicated as a complete regimen for the treatment of hiv-1 infection in adults who are antiretroviral treatment-naïve. coadministration of stribild is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of stribild and possible resistance) are listed in table 1 [see drug interactions (7.5), clinical pharmacology (12.3)]. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, stribild should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. antiretroviral pregnancy registry : to monitor fetal outcomes of pregnant women exposed to stribild, an antiretroviral pregnancy registry has been established. healthcare providers are encourag
stribild- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated
avera mckennan hospital - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - stribild® is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies/ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of stribild [see clinical studies (14)] . coadministration of stribild is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of stribild and possible resistance) are listed in table 1 [see drug interactions (7.5) and clinical pharmacology (12.3)]. pregnancy exposure registry there is a pregnancy exp
stribild- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated
gilead sciences, inc. - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - stribild® is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies/ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of stribild [see clinical studies (14)] . coadministration of stribild is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of stribild and possible resistance) are listed below [see drug interactions (7.5) and clinical pharmacology (12.3)]. - alpha 1-adrenoreceptor antagonist: alfuzosin - anticonv
stribild access- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated
gilead sciences, inc. - elvitegravir (unii: 4gdq854u53) (elvitegravir - unii:4gdq854u53), cobicistat (unii: lw2e03m5pg) (cobicistat - unii:lw2e03m5pg), emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - elvitegravir 150 mg - stribild™ is indicated as a complete regimen for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies/ml) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of stribild [see clinical studies (14)] . coadministration of stribild is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. these drugs and other contraindicated drugs (which may lead to reduced efficacy of stribild and possible resistance) are listed below [see drug interactions (7.5) and clinical pharmacology (12.3)]. - alpha 1-adrenoreceptor antagonist: alfuzosin - anticonvu
genvoya 150mg + 150mg + 200mg + 10mg oral solid ordinary tablets
gilead sciences inc - elvitegravir+cobicistat+emtricistabine+tenofovir alafenamide - oral solid ordinary tablets - 150mg + 150mg + 200mg + 10mg
genvoya film-coated tablet
gilead sciences limited (cork), ireland - cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide - film-coated tablet - 10, 150, 200, 150 mg
daruvir c tablet
delta pharma limited - cobicistat + darunavir - tablet - 150 mg + 800 mg
codavir tablet
opsonin pharma limited - cobicistat + darunavir - tablet - 150 mg + 800 mg